Oncopeptides AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONPPF research report →
About the company
Oncopeptides AB (publ) is a biotechnology company focused on developing pharmaceutical therapies to combat cancer. The firm's therapeutic innovations are intended for markets across the United States, Europe, and internationally. Its flagship product candidate, melflufen, is an advanced anti-cancer peptide drug conjugate specifically designed to treat adult patients afflicted with relapsed refractory multiple myeloma.
- CEO
- Sofia Heigis
- IPO
- 2020
- Employees
- 80
- HQ
- Stockholm, SE
Price Chart
- Market Cap
- $55.98M
- P/E
- -1.79
- P/S
- 4.88
- P/B
- 5.88
- EV/EBITDA
- -1.61
- Div Yield
- 0.00%
- Gross Margin
- 96.57%
- Op Margin
- -247.60%
- Net Margin
- -265.27%
- ROE
- 2083.70%
- ROIC
- -95.72%
- Revenue
- $31.65M · -10.14%
- Net Income
- $-284,607,000 · -14.25%
- EPS
- $-1.87 · 32.25%
- Op Income
- $-283,498,000
- FCF YoY
- 6.81%
- 52W High
- $0.27
- 52W Low
- $0.27
- 50D MA
- $0.27
- 200D MA
- $0.27
- Beta
- -0.55
- Avg Volume
- 8
Get TickerSpark's AI analysis on ONPPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ONPPF coverage
Recent articles, reports, and earnings notes.
No research on ONPPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONPPF report →Similar companies
Peers in the same neighborhood.